Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France

M. Hiligsmann*, J. -Y. Reginster

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)649-658
Number of pages10
JournalOsteoporosis International
Volume30
Issue number3
DOIs
Publication statusPublished - Mar 2019

Keywords

  • Cost-effectiveness
  • Economic evaluation
  • Osteoporosis
  • Risedronate
  • Treatment
  • QUALITY-OF-LIFE
  • ECONOMIC-EVALUATION
  • INTERVENTION THRESHOLDS
  • ORAL BISPHOSPHONATES
  • EXCESS MORTALITY
  • HIP FRACTURE
  • PERSISTENCE
  • ADHERENCE
  • HOSPITALIZATION
  • BURDEN

Cite this

@article{0158a84a6a9d445997b9247f5902e273,
title = "Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France",
keywords = "Cost-effectiveness, Economic evaluation, Osteoporosis, Risedronate, Treatment, QUALITY-OF-LIFE, ECONOMIC-EVALUATION, INTERVENTION THRESHOLDS, ORAL BISPHOSPHONATES, EXCESS MORTALITY, HIP FRACTURE, PERSISTENCE, ADHERENCE, HOSPITALIZATION, BURDEN",
author = "M. Hiligsmann and Reginster, {J. -Y.}",
year = "2019",
month = "3",
doi = "10.1007/s00198-018-04821-7",
language = "English",
volume = "30",
pages = "649--658",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer-Verlag London Ltd.",
number = "3",

}

Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. / Hiligsmann, M.; Reginster, J. -Y.

In: Osteoporosis International, Vol. 30, No. 3, 03.2019, p. 649-658.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France

AU - Hiligsmann, M.

AU - Reginster, J. -Y.

PY - 2019/3

Y1 - 2019/3

KW - Cost-effectiveness

KW - Economic evaluation

KW - Osteoporosis

KW - Risedronate

KW - Treatment

KW - QUALITY-OF-LIFE

KW - ECONOMIC-EVALUATION

KW - INTERVENTION THRESHOLDS

KW - ORAL BISPHOSPHONATES

KW - EXCESS MORTALITY

KW - HIP FRACTURE

KW - PERSISTENCE

KW - ADHERENCE

KW - HOSPITALIZATION

KW - BURDEN

U2 - 10.1007/s00198-018-04821-7

DO - 10.1007/s00198-018-04821-7

M3 - Article

VL - 30

SP - 649

EP - 658

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 3

ER -